-          CAHtalyst™ Adult Phase 3 Study Met Primary and Important Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and Enabling Glucocorticoid Dose Reduction While Maintaining Androstenedione Control        -          62.7% of Crinecerfont Participants Achieved a Physiologic Glucocorticoid Dose while Maintaining Androstenedione Control versus 17.5% of Placebo Participants     -          Favorable Trends in Endpoints Reflecting Consequences of Supraphysiologic Glu ...

Cardinal Health, Inc. (NYSE:CAH) Leerink Partners Healthcare Crossroads Conference May 29, 2024 10:00 AM ET Company Participants Matt Sims - Head, IR Aaron Alt - CFO Conference Call Participants Michael Cherny - Leerink Partners Michael Cherny Great. We'll get started now. Good morning, everyone. Welcome to the session of the Leerink Healthcare Crossroads Conference. I'm Mike Cherny, the Healthcare Tech and Distribution Analyst. Much more importantly, we have Cardinal Health CFO, Aaron Alt; and Head of IR, ...

Cardinal Health, Inc. (NYSE:CAH) Leerink Partners Healthcare Crossroads Conference May 29, 2024 10:00 AM ET Company Participants Matt Sims - Head, IR Aaron Alt - CFO Conference Call Participants Michael Cherny - Leerink Partners Michael Cherny Great. We'll get started now. Good morning, everyone. Welcome to the session of the Leerink Healthcare Crossroads Conference. I'm Mike Cherny, the Healthcare Tech and Distribution Analyst. Much more importantly, we have Cardinal Health CFO, Aaron Alt; and Head of IR, ...

Cardinal Health (CAH) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this prescription drug distributor have returned -6.9% over the past month versus the Zacks S&P 500 composite's +5% change. The Zacks Medical - Dental Supplies industry, to which Cardinal belongs, has gained 0.6% over this period. Now the key question is: Where could the stock be headed ...

Cardinal Health, Inc. (NYSE:CAH) BofA Securities 2024 Health Care Conference May 14, 2024 11:00 AM ET Company Participants Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants Unidentified Analyst CEO, Jason Hollar and CFO, Aaron Alt. First off, thank you both for joining us today. Now, Jason, you've been with the company since COVID began and we're finally entering a more normalized operating environment. And I guess as we sit here today, what are you most ...

Cardinal Health (CAH) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this prescription drug distributor have returned -10% over the past month versus the Zacks S&P 500 composite's -1.6% change. The Zacks Medical - Dental Supplies industry, to which Cardinal belongs, has lost 4.9% over this period. Now the key question is: Where could the stock be headed in the near te ...

Core Insights - Cardinal Health reported revenue of $54.91 billion for the quarter ended March 2024, reflecting an 8.8% increase year-over-year, but a -1.63% miss against the Zacks Consensus Estimate of $55.82 billion [1] - The earnings per share (EPS) for the quarter was $2.08, up from $1.74 in the same quarter last year, resulting in a positive surprise of +6.67% compared to the consensus estimate of $1.95 [1] Revenue Breakdown - Pharmaceutical revenue was $50.65 billion, which is an 8.2% increase year-over-year but below the average estimate of $51.89 billion from four analysts [2] - Medical revenue was reported at $3.11 billion, significantly lower than the estimated $3.61 billion, representing a -15.5% change year-over-year [2] - Corporate revenue showed a loss of -$20 million, better than the average estimate of -$2.73 million, with a year-over-year change of +233.3% [2] Segment Profit Analysis - Medical segment profit was $20 million, falling short of the average estimate of $103.19 million from four analysts [2] - Pharmaceutical segment profit was $580 million, also below the estimated $606.65 million from four analysts [2] Stock Performance - Cardinal Health's shares have returned -7.9% over the past month, compared to a -4.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Q3 FY24 Earnings Cardinal Health, Inc. May 2, 2024 ...

Cardinal Health, Inc. (NYSE:CAH) Q3 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Matt Sims - VP, IR Jason Hollar - CEO Aaron Alt - CFO Conference Call Participants Lisa Gill - JP Morgan Michael Cherny - Leerink Partners George Hill - Deutsche Bank Allen Lutz - Bank of America Kevin Caliendo - UBS Eric Percher - Nephron Research Stephanie Davis - Barclays Eric Coldwell - Baird Elizabeth Anderson - Evercore ISI Stephen Baxter - Wells Fargo Lucas Romanski - TD Cowen Daniel Grosslig ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |--------------------------------------------------------------------------------------------|-----------------------------------| | For the transition period from | __ ...